Larvol Delta - Asher-Bio-Presents-New-Preclinical-Data-at-SITC-2022-Further-Supporting-Advancement-of-AB248-and-AB821-as-Highly-Differentiated-Cistargeted-Cancer-Immunotherapies

AB248 - Asher Biotherap

https://www.businesswire.com/news/home/20221110005064/en/Asher-Bio-Presents-New-Preclinical-Data-at-SITC-2022-Further-Supporting-Advancement-of-AB248-and-AB821-as-Highly-Differentiated-Cis-targeted-Cancer-Immunotherapies

Nov 10, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next